RedHill Biopharma Gets Commercialization Agreement With ParaPRO

RedHill Biopharma (NASDAQ:RDHL) announced that it has entered into a commercialization agreement with ParaPRO.

As quoted in the press release:

Granting RedHill the exclusive rights to promote Esomeprazole Strontium Delayed-Release Capsules to gastroenterologists in certain U.S. territories.

Esomeprazole Strontium DR Capsules 49.3 mg is a prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD), risk reduction of NSAID-associated gastric ulcer, H. pylori eradication to reduce the risk of duodenal ulcer recurrence and for pathological hypersecretory conditions, including Zollinger-Ellison syndrome1. Esomeprazole Strontium DR Capsules 49.3 mg is a proprietary prescription drug approved by the FDA under a New Drug Application (NDA).

Click here to read the full press release.

Get the Latest Pharmaceutical Investing Stock Information

Get the latest information about companies associated with Pharmaceutical Investing delivered directly to your inbox.

Pharmaceutical

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Comments

Leave a Reply